| abstract |
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to new imidazo[4,5-b]pyrazine derivatives of general formulaor to its pharmaceutically acceptable salt wherein: Rrepresents either aryl unsubstituted or substituted by one of the groups: halogen, hydoxyl, Calkyl, Calkoxyl, NH, NHCalkyl, N(Calkyl), NHCalkylCalkoxy, Calkylhydroxy, -C(O)NH, -C(O)OCalkyl, -C(O)NH Calkyl, cyano, carboxy, heteroaryl and heterocycloalkyl; or heteroaryl unsubstituted or substituted by one of the groups: Calkoxy, hydroxy, -Calkyl, NHand NHCalkyl; heterocycloalkyl unsubstituted or substituted by one group =O; and Rrepresents H; unsubstituted Calkyl; Calkyl substituted by Ccycloalkyl unsubstituted or substituted by one group specified in amino, hydroxyl, Calkoxy, or heterocycloalkyl unsubstituted or substituted by 1-2 groups specified in =O, Calkyl; or Ccycloalkyl substituted by one group specified in hydroxyl, Calkoxyl, CalkylCalkoxy, Calkylhydroxy, CONH; or substituted ir unsubstituted heterocycloalkyl; wherein aryl represents an aromatic structure consisting of 6-10 carbon atoms containing one ring or two condensed rings; wherein heteroaryl represents a 5-10-member aryl ring system containing 1-2 heteroatoms specified in nitrogen, oxygen and sulphur; wherein heterocycloalkyl represents a 5-9-member nonaromatic cycloalkyl wherein 1-2 heteroatoms specified in nitrogen and oxygen; provided the compound does not represent 1,3-dihydro-5-phenyl-2H-imidazo[4,5-b]pyrazin-2-one. Also, the invention refers to the specific imidazo[4,5-b]pyrazine derivatives, to a based pharmaceutical composition, to a method of treating or preventing cancer, inflammatory conditions, immunological diseases, metabolic conditions, and to a method of kinase inhibition in a cell expressing said kinase.EFFECT: there are produced new imidazo[4,5-b]pyrazine derivatives showing effective biological properties.17 cl, 2 tbl, 210 ex |